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ABSTRACT
Background Evidence from observational
studies suggests an increased risk of HIV
acquisition among women using depot
medroxyprogesterone acetate (DMPA)
contraception.
Methods Within the context of a South African
programme to increase women’s access to the
intrauterine contraceptive device (IUD), we
conducted a pragmatic, open-label, parallel-arm,
randomised controlled trial (RCT) of the IUD
versus injectable progestogen contraception (IPC)
at two South African hospitals. The primary
outcome was pregnancy; secondary outcomes
included HIV acquisition. Consenting women
attending termination of pregnancy services were
randomised after pregnancy termination
between July 2009 and November 2012.
Condoms were promoted for the prevention of
sexually transmitted infections. Voluntary HIV
testing was offered at baseline and at 12 or
more months later. Findings on HIV acquisition
are reported in this article.
Results HIV acquisition data were available for
1290 initially HIV-negative women who
underwent a final study interview at a median of
20 months after randomisation to IPC or an IUD.
Baseline group characteristics were comparable.
In the IPC group, 545/656 (83%) of participants
received DMPA, 96 (15%) received injectable
norethisterone enanthate, 14 (2%) received the
IUD and one received oral contraception. In the
IUD group 609 (96%) received the IUD, 20 (3%)
received IPC and 5 (1%) had missing data.
According to intention-to-treat analysis, HIV
acquisition occurred in 20/656 (3.0%) women in
the IPC arm and 22/634 (3.5%) women in the
IUD arm (IPC vs IUD, risk ratio 0.88; 95%
confidence interval 0.48–1.59; p=0.7).
Conclusions This sub-study was underpowered
to rule out moderate differences in HIV risk, but
confirms the feasibility of randomised trial
methodology to address this question. Larger
RCTs are needed to determine the relative risks
of various contraceptive methods on HIV
acquisition with greater precision.
Trial registration number Pan African Clinical
Trials Registry number PACTR201409000880157
(04-09-2014).
BACKGROUND
The possibility that hormonal contracep-
tion, particularly depot medroxyproges-
terone acetate (DMPA), increases HIV
Key message points
▸ The net physiological and behavioural
effects of hormonal contraception on
HIV acquisition cannot be predicted
from existing animal models and obser-
vational clinical data.
▸ To date there is no evidence from ran-
domised controlled trials (RCTs) which
confirms a greater risk with injectable
progestogens than with the copper
intrauterine device.
▸ Larger RCTs are needed to determine
the relative risks of HIV acquisition
with various contraceptive methods.
▸ Contraception providers should con-
tinue to counsel women on the mea-
sures available to prevent HIV
acquisition.
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acquisition has been of concern for almost three
decades. DMPA increases the susceptibility of non-
human primates to simian immunodeficiency virus
(SIV) infection,1 2 and studies in mice suggest that
DMPA may increase mucosal permeability, promote
tissue inflammation, and increase susceptibility to viral
infection (herpes simplex type 2).3 In DMPA contra-
ception users, mechanisms such as alterations in local
and systemic immunity, cervicovaginal epithelial thin-
ning or disruption, changes in vaginal flora, and
increased risk of cervicovaginal infections might play
a role in increasing HIV risk.4–6 However, a review of
the biological link between HIV risk and hormonal
contraception concluded that there is a paucity of
rigorous research to support these potential
mechanisms.7
Following the conduct of an individual patient data
meta-analysis derived from observational studies,8
which found the HIV acquisition risk with DMPA
compared with no hormonal contraception [adjusted
hazard ratio (aHR)] to be 1.22, (95% confidence inter-
val (95% CI) 0.99–1.50; five studies), and another
updated systematic review that estimates a HR of 1.4,9
there remains considerable uncertainty about this
potential association and the global public health
implications. Observational studies are informative
but have inherent methodological limitations as
they are not designed to determine whether an associ-
ation might be causal, and are unable to control for
unknown confounders or exclude the possibility of
a difference in inherent risk for HIVacquisition related
to a woman’s contraceptive choice. In addition, inject-
able progestogen (progestin) contraception (IPC) is a
widely used and acceptable method of contraception
in many low- and middle-income countries, and under-
mining its use as a contraceptive option without robust
evidence of harm could have a substantial impact on
unintended pregnancy and maternal mortality.
DMPA is the most widely used contraceptive
method in South Africa, where the prevalence of HIV
infection among women aged between 20 and
34 years old was 31.6% in 2012.10 In this article we
report HIV acquisition data from a prespecified sub-
study of a pragmatic randomised controlled trial
(RCT) of the copper intrauterine contraceptive device
(IUD) versus IPC conducted within the context of a
South African programme to increase women’s access
to the IUD. The primary article on pregnancy rates
and method discontinuation has been published in
BMC Reproductive Health.11 The sub-study objective
was to determine whether IPC and the IUD differ in
their effect on HIV acquisition.
METHODS
Design and participants
The trial was a pragmatic, open-label, parallel-arm
RCT conducted at two Eastern Cape hospitals, Frere
Hospital and Cecelia Makiwane Hospital, in South
Africa. Women attending termination of pregnancy
services at the study sites who requested long-term
contraception and met the inclusion criteria (i.e.
intended to continue contraception for at least 1 year,
were 16–45 years old, had no evidence of active
pelvic infection on history and clinical examination,
had no contraindications to IPC or IUD use, were pre-
pared to use either method of contraception, under-
stood the participant information form, and were
willing to sign informed consent) were offered partici-
pation in the trial.
Randomisation
Between July 2009 and November 2012, consenting
women were randomly allocated to an IUD or IPC as
per the methods previously published.11 In brief, ran-
domisation was performed according to a computer-
generated random sequence in balanced blocks of
variable size with a randomisation ratio of 1:1, and
participants were allocated to study arms via sequen-
tially numbered, sealed, opaque envelopes containing
the group allocations once they had been entered
onto the trial register. The study protocol identified
the IUD as the experimental intervention as it had
been recently introduced, and DMPA, the most com-
monly used method in our setting, as the comparator.
For this HIV acquisition sub-study, results are pre-
sented with DMPA as the experimental arm for con-
sistency with other studies in this field.
Prespecified outcomes
The primary outcome of the main study was preg-
nancy. Secondary outcomes were method discontinu-
ation, side effects and HIV acquisition. Findings on
HIV acquisition, evaluated in the subgroup of partici-
pants that were HIV-negative at baseline, are the focus
of this article.
Procedure
Participants randomised to the IUD arm had their IUD
inserted by the hospital staff after their termination
of pregnancy, which was usually performed by manual
vacuum aspiration. Similarly, in the IPC arm, the first
injection was administered by hospital staff according
to routine practice. In most instances DMPA was used.
However, as this was a pragmatic trial within the
routine services, allowance was made for the use of
NETat the discretion of the provider. Women received
no additional reminders to support continuation with
the allocated contraception method.
Professional nurses working as research assistants
recorded participant baseline details on a paper case
report form and administered follow-up question-
naires by telephone at 3, 6, 9 and 12 months after
randomisation. All women were offered counselling
and voluntary HIV testing at baseline, according to
national health policy, using rapid tests or laboratory-
based ELISA tests. Those with positive results were
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offered a CD4 count and treatment according to
national health guidelines.
At the 12-month telephone interview, participants
were invited to attend a final interview at the study
site and offered a follow-up HIV test, if appropriate.
During the telephone interview, participants were
asked the date and result of their most recent HIV test
(and CD4 count, if positive), along with the name of
the clinic where the result could be verified, and
which method of contraception they were currently
using, if any. For participants who did not attend the
research site for a follow up HIV test at least
12 months after randomisation, the telephone report
of their last result was used. Continued attempts were
made to contact women until the close of the study,
resulting in long follow-up times in some women.
Sample size and analysis
The sample size calculation was based on the primary
outcome (pregnancy). As previously published, to
detect a reduction in pregnancy rates from 2.5% to
1.5%, we calculated that we needed 6546 participants
[α=0.05, β=0.20; Epi Info™ 7 statistical software
(Centres for Disease Control and Prevention)] and
planned to recruit a total sample size of 7000 women
to allow for loss to follow-up. Based on an HIV preva-
lence of 25%, this would have allowed for a sample
size for the sub-study of HIV-negative women of
approximately 5250 (sufficient to detect an increase in
HIVacquisition risk from 2% to 3.3%). Sub-study data
on HIVacquisition for IPC versus IUD arms were com-
pared according to intention-to-treat (ITT) and per
protocol analyses. We compared event rates as risk
ratios (RR) with 95% confidence intervals (95% CIs).
Values for p were calculated in Epi Info 7 using the
Chi-squared (χ2) test with Mantel-Haenszel correction
or, for small numbers, the Fisher’s exact test. To check
the robustness of the findings on HIV acquisition, we
performed sensitivity analysis excluding women with
self-reported HIV test results.
Ethics, consent and permissions
Ethical approval for the trial was obtained from the
University of the Witwatersrand Committee for
Research on Human Subjects, South Africa, on 25
April 2008, clearance certificate M080466. Signed
informed consent to participate in the study was
obtained from all participants. No payments or other
incentives were offered, other than payment of trans-
port costs for the final follow-up visit.
Trial registration
Prospective registration of the protocol with the South
African National Clinical Trials Register was under-
taken on 15 September 2008 (Verification Code:
0-953). It was subsequently found not to have been
logged by the system, and was re-registered with the
Pan African Clinical Trials Registry on 4 September
2014 (PACTR201409000880157).
RESULTS
The trial closed early due to international concerns
raised about the possible association between DMPA
and HIVacquisition, following publication of an obser-
vational study reporting increased HIV acquisition
among women who chose DMPA contraception,12 and
the subsequent plan by international collaborators to
conduct a large, multicentre trial to address the
DMPA/HIV question, following a World Health
Organization (WHO) Technical Consultation.13 14
At trial closure, 2493 (36%) of the target sample
had accrued, with 1246 and 1247 women randomised
to the IPC and IUD arms, respectively. Some 475
(19%) women tested HIV-positive at baseline, 14
(0.6%) had missing test results, 243 (10%) declined
testing and 9 (0.4%) had missing data on testing
status. For the 1752 (70.3%) women who tested
HIV-negative at baseline (878 and 874 women in the
IPC and IUD groups, respectively), and for those with
follow-up data available, baseline characteristics of the
two arms were similar (Figure 1 and Table 1).
Follow-up HIV test results, by investigator-
performed HIV test (814/1290; 63%) or self-report
(476/1290; 37%), were available for 1290 (74%) of
these women. Thus, a total of 656 and 634 women
had negative baseline HIV tests and subsequent HIV
test results in the IPC and IUD study arms, respect-
ively, and were included in the ITT analysis on HIV
acquisition. Loss to follow-up for this outcome, due
to loss of contact with participants or lack of a repeat
HIV test, occurred with a similar frequency in the IPC
(25%) and IUD (27%) study arms.
The time from enrolment to follow-up HIV test was
similar for both study arms, with a median of
19.4 months in the IPC arm [interquartile range
(IQR) 15.6–27.7] and 20.0 months (IQR 16.2–27.8)
in the IUD arm. In the IPC group, 545/656 (83%) of
participants received DMPA, 96 (15%) received inject-
able norethisterone enanthate (NET), 14 (2%)
received the IUD and one received oral contraception.
In the IUD group, 609 (96%) received the IUD, 20
(3%) received IPC and 5 (1%) had missing data. At
follow-up, 553/656 (84%) and 463/634 (73%),
respectively, reported currently using the allocated
method. The incidence of HIV acquisition according
to ITT analysis was 20/656 (3.0%) in the IPC arm and
22/634 (3.5%) in the IUD arm (IPC vs IUD, RR 0.88;
95% CI 0.48–1.59; p=0.7) (Table 2).
For participants that had HIV tests performed by
research staff, as opposed to those self-reporting HIV
test results, the RR for HIV acquisition was 0.78
(95% CI 0.38–1.60), with 13/411 (3.2%) acquiring
HIV during the study period in the IPC arm com-
pared with 17/403 (4.1%) in the IUD arm.
Per protocol analysis according to interventions
received at baseline yielded similar results, with 21/
661 (3.2%) and 21/623 (3.4%) acquiring HIV among
those who received IPC and IUDs, respectively
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(p=0.8). Some 19/558 (3.4%) women given DMPA
at baseline and 2/103 (1.9%) women given NET at
baseline acquired HIV. Out of five women with missing
data on the method received at baseline and one who
received oral contraception, none acquired HIV.
During follow-up attempts, research assistants
learned that two women in the sub-study had died;
one women aged 18 years, who received DMPA, died
from eclampsia 16 months after enrolment; the other
women, aged 20 years, who received NET, died from
an asthmatic attack 9 months after enrolment.
DISCUSSION
Our sub-study has several important limitations: The
trial was terminated prematurely following a meeting
of experts at the WHO headquarters in Geneva in
2012 that highlighted a perceived global need for a
rigorous, well-funded and high-profile trial to answer
the question regarding HIV acquisition.14 This global
imperative did not exist at the time that our study was
commenced. Early closure meant that the sample size
for the sub-study did not have the power to exclude
the possibility of a meaningful difference in effect on
HIV acquisition between the two contraceptive
methods tested. This limited its value to that of a pilot
feasibility study. The contraceptive care and follow-up
of the women took place within the routine health
services, and was not under the supervision of the
research team. The determination of HIV status at
follow-up was based on rapid tests or laboratory-based
ELISA tests, either performed by our research staff or
self-reported by the women. In the latter case there
may have been under-reporting. However, the women
with self-reported tests provided the date and name of
the clinic where the test was performed, and all self-
reported results that could be confirmed by contacting
Figure 1 Flow of participants in sub-study analysis on HIV acquisition. IPC, injectable progestogen contraception; IUD, intrauterine
device; –ve, negative.
Table 1 Baseline data of sub-study participants (HIV-negative at enrolment) expressed as numbers (%) or mean values (SD]
All participants with HIV-negative status at baseline Participants with follow-up
IPC group (N=878) IUD group (N=874) IPC group (N=656) IUD group (N=634)
Characteristic n (%) or mean [SD] N n (%) or mean [SD] N n (%) or mean [SD] N n (%) or mean [SD] N
Age (years) 25.7 [6.2] 873 26.0 [6.3] 867 26.0 [6.3] 655 26.0 [6.3] 631
Weight (kg) 69.9 [16.3] 860 71.2 [18.2] 853 70.3 [16.2] 644 71.9 [18.2] 615
Previous miscarriage 76 (8.7) 878 85 (9.7) 874 66 (10.1) 656 68 (10.7) 634
Previous caesarean section 98 (11.2) 878 112 (12.8) 874 72 (11.0) 656 76 (12.0) 634
Previous pelvic sepsis* 162 (18.5) 878 170 (19.5) 874 120 (18.3) 656 170 (19.5) 634
Hypertension 4 (0.5) 878 5 (0.6) 874 2 (0.3) 656 3 (0.5) 634
Diabetes mellitus 1 (0.1) 878 3 (0.3) 874 1 (0.1) 656 3 (0.5) 634
Previous contraception use
IPC 565 (71.7) 788 562 (71.4) 787 438 (75) 586 425 (75) 566
OC 48 (5.8) 830 64 (7.7) 827 32 (5.2) 616 44 (7.4) 598
IUD 1 (0.1) 830 1 (0.1) 827 1 (0.1) 616 1 (0.1) 598
*South Africa implements the World Health Organization Primary Care model whereby women with certain signs and symptoms are treated ‘syndromically’
for assumed pelvic infection. This may result in over-diagnosis.
IPC, injectable progestogen contraception; IUD, intrauterine device; OC, oral contraception; SD, standard deviation.
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the relevant clinics were found to be correct. Any sys-
tematic bias due to under-reporting is likely to have
affected both arms equally. In addition, the RR for
HIV acquisition remained unchanged after exclusion
of the self-reported results. We were not able to
exclude ‘window period’ false-negative results at base-
line or at follow-up, which would also be expected to
affect both arms equally.
Within the IPC group, the characteristics of women
who received NET may have differed from those who
received DMPA; for this reason we have not drawn
conclusions from the per protocol comparison of
results in women who received NET or DMPA, which
were reported for completeness. The ITT analysis
retains the comparability of the arms as originally ran-
domised [(DMPA plus NET) vs IUD]. If, for example,
DMPA was associated with higher HIV acquisition risk
than both NET and the IUD, use of NET by about
16% of women would have reduced the magnitude of
the difference between IPC and IUD HIV acquisition
risk but would not have eliminated it.
An important aspect of interpretation is that one
cannot assume that the IUD does not alter HIV acqui-
sition risk. Although non-hormonal, the effect of
IUD-related inflammation is unknown; thus IUD use
could affect HIV risk in either direction. Trials such as
ours assess comparative risks between methods, not
absolute risks. For example, similarity between
methods could be due to no effect of either method,
increased risk with both methods, or reduced risk
with both methods. Comparative risks are of import-
ance to women who desire contraception and wish to
choose between alternative methods.
Keeping in mind the trial limitations, our findings
suggest that any difference in the risk of HIV acquisi-
tion with IPC compared with the IUD is unlikely to
be large. Some variation from the true effects in
either direction may have been introduced by the loss
to follow-up, method discontinuation and the use of
NET in 16% of participants in the IPC arm. Most
importantly, the study was not powered to detect a
modest effect due to early closure of the trial.
Therefore, we cannot rule out the possibility of an
effect in either direction large enough to have import-
ant public health implications. An international
Technical Consultation held at the WHO in Geneva
on 31 January 2012 concluded that the WHO should
continue to recommend that there are no restrictions
on the use of hormonal contraceptive methods for
women at high risk of HIV, due to insufficient evi-
dence of an association.14 DMPA is a widely accepted
and highly effective contraceptive method that is esti-
mated to prevent thousands of maternal and infant
deaths each year by reducing unintended pregnancy.15
A modelling of competing risks suggests that reducing
DMPA use may only have public health benefits if
the true HIV acquisition risk effect size approaches
an odds ratio (OR) of 2.19.15 This modelling also
showed that countries such as South Africa with high
HIV incidence and high IPC use would see a reduc-
tion in total deaths with removal of IPC if there is a
strong association between DMPA and HIV acquisi-
tion.15 However, for countries with high IPC use and
high maternal mortality compared with HIV inci-
dence, such as Bangladesh, Egypt and Indonesia,
reducing IPC use would increase net deaths of
women regardless of the OR estimate used.15 The net
global effect of withdrawing IPC as a contraceptive
option on deaths has been estimated to be 47 000
fewer deaths per year with an OR of 2.19, 3400
more deaths with an OR of 1.2, and at least 16 000
more deaths with an OR of 1.0, with a net increase
in deaths in all countries.15
The strengths of our study include the potential for
the findings to be generalisable to similar healthcare
settings because the study took place within the
routine health services, thus reflecting ‘typical use’
outcomes. The trial also addresses several factors
which have a bearing on ongoing efforts to answer
the HIV acquisition risk and hormonal contraception
research question. First, it shows that many women
without a specific preference for a contraceptive
method were willing to agree to randomisation
without any financial remuneration or other benefits.
The acceptability and feasibility of randomisation is
supported by the fact that discontinuation rates at
final follow-up for both IPC and IUD were relatively
low at a median follow up of 20 months.11
HIV prevention and contraception are two compet-
ing public health concerns and a framework for
addressing the ethical challenges this poses for public
health practice has been suggested.16 However, uncer-
tainty about the relative effects of contraception on
HIV may continue to undermine family planning and
HIV prevention public health strategies, and impact
Table 2 Results for HIV acquisition according to intention-to-
treat and per protocol analyses (initial method received)
Analysis
HIV acquisition
Effect estimate
(IPC vs IUD)
pn (%) N RR 95% CI
ITT analysis (i.e. according to group allocation)
IPC 20 (3.0) 656 0.88 0.48–1.59 0.7
IUD 22 (3.5) 634 1
PP analysis (i.e. according to initial method received)
IPC 21 (3.2) 661 0.94 0.52–1.71 0.8
DMPA 19 (3.4) 558 1.01 0.55–1.86 1.0
NET 2 (1.9) 103 0.58 0.14–2.42 0.4
IUD 21 (3.4) 623 1
OC 0 (0) 1
Missing data 0 (0) 5
CI, confidence interval; DMPA, depot medroxyprogesterone acetate;
IPC, injectable progestogen contraception; ITT, intention-to-treat; IUD,
intrauterine contraceptive device; NET, norethisterone enanthate; OC, oral
contraception; PP, per protocol; RR, risk ratio.
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service user confidence, without higher quality evi-
dence. Data on the risk of HIV acquisition with other
long-acting hormonal contraceptives such as implants
are very limited, and it cannot be assumed that HIV
acquisition risk will differ substantially between
DMPA and these other contraceptive options without
better evidence. Contraception providers should con-
tinue to counsel women on the measures available,
including condom use and pre-exposure prophylaxis,
to prevent HIV acquisition.
CONCLUSIONS
This study serves as a ‘pilot’ study to inform the feasi-
bility and likely range of outcomes for a fully powered
study. It is impossible to estimate the net effect of
both known and unknown biological and behavioural
adverse and protective effects of various contraceptive
methods, including DMPA and other long-acting hor-
monal contraceptives, on HIV acquisition without
more rigorous research. Our sub-study confirms the
feasibility of randomised trial methodology to address
this question. Robust evidence from larger RCTs of
the relative effects of various contraceptive methods
on HIV acquisition would provide a sound basis for
global programmes to simultaneously promote safe
contraception and reduce HIV incidence.
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